Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as elements of the endocannabinoid system (ECS). We analysed the occurrence...

ver descrição completa

Detalhes bibliográficos
Autores: Galán‑Ganga, M. (Marcos)|||/items/435ae0ad-3f4a-466d-a2e7-1676381292dc, Rodríguez-Cueto, C. (Carmen)|||/items/7e190003-f3cf-479d-a549-67193c9ca9d1, Merchán-Rubira, J. (Jesús)|||/items/f134417c-5612-4947-96ae-f79ea72ef00e, Hernández-Pérez, F. (Félix)|||/items/b7e91068-ca78-40da-8347-87d736b13f77, Avila, J. (Jesús)|||/items/2757ce4f-661c-40c0-987f-bc824240a9b6, Posada-Ayala, M. (María)|||/items/a867946c-15cf-411d-91e8-be42da6bb325, Lanciego-Pérez, J.L. (José Luis)|||/items/d2d4dbfe-4daf-4103-89ec-2ebf41b65cd1, Luengo, E. (Enrique)|||/items/e6882206-a09c-47d4-9598-dca740ecedfc, García-López, M. (Manuela)|||/items/6bc6e2b3-56ec-4710-a35e-f46c96691346, Rábano, A. (Alberto)|||/items/a56b32f6-4de5-4e3f-b1f3-b5eafbfb6670, Fernández-Ruiz, J. (Javier)|||/items/1f1e03f8-41d1-4324-b760-a3bc98f17c85, Lastres-Becker, I. (Isabel)|||/items/b0790e31-344b-4ca4-81ff-7f50b9a46e37
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/114890
Acesso em linha:https://hdl.handle.net/10171/114890
Access Level:acceso abierto
Palavra-chave:TAU
Cannabinoid receptor
CB2
Alzheimer’s disease
Neurodegeneration
Neuroinfammation
Descrição
Resumo:Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as elements of the endocannabinoid system (ECS). We analysed the occurrence of changes in the ECS in tauopathies and their implication in the pathogenesis. By integrating gene expression analysis, immunofluorescence, genetic and adeno-associated virus expressing TAU mouse models, we found a TAU-dependent increase in CB2 receptor expression in hippocampal neurons, that occurs as an early event in the pathology and was maintained until late stages. These changes were accompanied by alterations in the endocannabinoid metabolism. Remarkably, CB2 ablation in mice protects from neurodegeneration induced by hTAUP301L overexpression, corroborated at the level of cognitive behaviour, synaptic plasticity, and aggregates of insoluble TAU. At the level of neuroinflammation, the absence of CB2 did not produce significant changes in concordance with a possible neuronal location rather than its classic glial expression in these models. These findings were corroborated in post-mortem samples of patients with Alzheimer’s disease, the most common tauopathy. Our results show that neurons with accumulated TAU induce the expression of the CB2 receptor, which enhances neurodegeneration. These results are important for our understanding of disease mechanisms, providing a novel therapeutic strategy to be investigated in tauopathies.